References:
- Melrose D. Bitter pills: medicines and the third world poor Oxford,
United Kingdom Oxfam, 1982.
- US Food and Drug Administration. Advisory Review Panel on OTC
Laxative, Antidiarrheal, Emetic, and Antiemetic Drug Products. Federal
Register, March 21, 1975;40:12,902–10.
- US Food and Drug Administration. Laxative drug products for
over-the-counter human use; proposed amendment to the tentative final
monograph. Federal Register, September 2, 1997;62:46,223–7.
- Dunnick JK, Hailey JR. Phenolphthalein exposure causes multiple
carcinogenic effects in experimental model systems. Cancer Res
1996;56:4922–6.
- Sipe HJ Jr, Corbett JT, Mason RP. In vitro free radical metabolism of
phenolphthalein by peroxidases. Drug Metab Dispos 1997;25: 468–80.
- Ravdin PM, van Beurden M, Jordan VC. Estrogenic effects of
phenolphthalein on human breast cancer cells in vitro. Breast Cancer
Res Treat 1987;9:151–4
- Nakamura GJ, Schneiderman LJ, Klauber MR. Colorectal cancer and bowel
habits. Cancer 1984;54:1475–7.
- Kune GA, Kune S, Field B, Watson LF. The role of chronic constipation,
diarrhea, and laxative use in the etiology of large-bowel cancer. Data
from the Melbourne Colorectal Cancer Study. Dis Colon Rectum
1988;31:507–12.
- Kune GA. Laxative use not a risk for colorectal cancer: data from the
Melbourne Colorectal Cancer Study. Z Gastroenterol 1993;31:140–3.
- Sonnenberg A, Muller AD. Constipation and cathartics as risk factors
of colorectal cancer: a meta-analysis. Pharmacology 1993;47 Suppl
1:224–33.
- Le Marchand L, Wilkens LR, Kolonel LN, Hankin JH, Lyu LC. Associations
of sedentary lifestyle, obesity, smoking, alcohol use, and diabetes
with the risk of colorectal cancer. Cancer Res 1997;57:4787–94.
- Jacobs EJ, White E. Constipation, laxative use, and colon cancer among
middle-aged adults. Epidemiology 1998;9:385–91.
- Ghadirian P, Maisonneuve P, Perret C, Lacroix A, Boyle P. Epidemiology
of sociodemographic characteristics, lifestyle, medical history, and
colon cancer: a case–control study among French Canadians in
Montreal. Cancer Detect Prev 1998;22:396–404.
- FDA Drug Safety Communication: FDA limits usage of Nizoral
(ketoconazole) oral tablets due to potentially fatal liver injury and
risk of drug interactions and adrenal gland problems. UCM 362444: 26
July 2013.
- European Medicines Agency recommends suspension of marketing
authorisations for oral ketoconazole. Benefit of oral ketoconazole
does not outweigh risk of liver injury in fungal infections. EMA/
458028/2013. 26 July 2013.
- Patricia F. Coogan, Lynn Rosenberg, Julie R. Palmer, Brian L. Strom,
Ann G. Zauber, Paul D. Stolley, Samuel Shapiro. Phenolphthalein
Laxatives and Risk of Cancer. Journal of the National Cancer
Institute, Vol. 92, No. 23, December 6, 2000.
- H. Karl Greenblatt and David J. Greenblatt. Liver Injury Associated
With Ketoconazole: Review of the Published Evidence. The Journal of
Clinical Pharmacology 54(12) 1321–1329